ICYMI: Biosimilar BI 695501 Has Similar Safety and Efficacy to Adalimumab for the Treatment of Crohn’s Disease: VOLTAIRE-CD Study
Listen now
Description
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial,” by Hanauer S, Liedert B, Balser S, et al. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):816-825. Epub 2021 Aug 11.
More Episodes
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Bharati Kochar, MD, MS discuss “A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial,” by Noor NM...
Published 05/15/24
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Next-generation multitarget stool DNA test for colorectal cancer screening,” by T, Porter K, Zella J, et al. N Engl J Med. 2024; 390: 984-93.
Published 05/15/24
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Ahmad Abu-Heija, MBBS discuss “Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial,” by Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et...
Published 05/15/24
Links
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
